The purpose of the study is to learn more about ways to help patients understand and manage side-effects from hormone therapy. The investigators will use the information from this study to design future studies to better understand how our well our tools work to help patients monitor and manage symptoms from hormone therapy and to stay on their hormone therapy for the recommended period of time.
Participants must identify as a woman
Participants must be age 18 or older
Participants must have a diagnosis of Stage 0, I, II, or III HR+ breast cancer
Participants must have started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole) within 16 weeks of study registration.
Metastatic (Stage IV) breast cancer
Male gender
Prior treatment with endocrine therapy for breast cancer
Communication difficulties such as: Uncorrected or uncompensated hearing and/or vision impairment, uncorrected or uncompensated speech defects, uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks
Parallel
Digital Endocrine therapy Symptom Monitoring and Education Intervention
BehavioralPatients will receive text messages with links to symptom monitoring surveys and educational materials on possible symptoms from endocrine therapy.
System Usability Scale (SUS)
Determined via patient reported satisfaction with the intervention; final score from 0-100 (higher score represents better usability)
Feasibility- recruitment rates and intervention completion rates
Evaluated via rates of recruitment and intervention completion
Endocrine therapy adherence
Proportion of days participant takes medication
FACTS-ES likert variables
Side effects of endocrine therapy
Click on the lead sponsor to view all of their trials.
Abramson Cancer Center at Penn Medicine
Lead sponsor
Fox Chase Cancer Center
Collaborator
National Cancer Institute (NCI)
Collaborator
